Pacts In Medtech, Jan/Feb 2018
Derived from Strategic Transactions, Informa’s premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech highlights notable technology alliances, R&D partnerships and commercial collaborations. In this edition, we look at industry pacts that were sealed in the first two months of 2018.
You may also be interested in...
Pharmaceuticals group GlaxoSmithKline has launched a new $50m venture capital fund dedicated to investing in “bioelectronic medicines”, an emerging generation of neuromodulation technologies designed to treat diseases ranging from autoimmune and inflammatory conditions to respiratory disorders.
Two $1bn+ alliances were penned in October. Financing reached $7.7bn in biopharma, $636m in device, and $140m in diagnostics.
During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.